Newater Technology Inc  

(Public, NASDAQ:NEWA)   Watch this stock  
Find more results for NEWA
+0.67 (5.50%)
Feb 23 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 11.40 - 13.10
52 week 7.32 - 21.00
Open 12.00
Vol / Avg. 99,858.00/113,081.00
Mkt cap 138.88M
P/E 63.74
Div/yield     -
EPS 0.20
Shares 10.60M
Beta     -
Inst. own 0%

Key stats and ratios

Q2 (Jun '17) 2016
Net profit margin 0.22% 19.82%
Operating margin 1.91% 11.36%
EBITD margin - 12.88%
Return on average assets 0.16% 17.23%
Return on average equity 0.30% 33.55%
Employees 95 -
CDP Score - -


C/O Yantai Jinzheng Eco-Technology Ltd. 8 Lande Road, Laishan District
YANTAI, SDG 264000
+86-535-6212280 (Phone)

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Newater Technology, Inc. is a wastewater purification treatment company. The Company is focused on the development, manufacture and sale of disk tube reverse osmosis (DTRO) and disk tube nanofiltration (DTNF) membrane filtration products that are used in the treatment, recycling and discharge of wastewater. The DTRO membrane and DTNF membrane is used to treat and recycle wastewater. The Company also supplies hardware and engineered systems necessary to implement integrated solutions with DTRO and DTNF products. The Company provides engineering support and installation, technical advice and service, and other project-related solutions to filter wastewater into clean water. The company provides services to chemical and energy industries. The Company also offers traditional wastewater treatment solutions, such as activated carbon and resins.

Officers and directors

Yuebiao Li Chairman of the Board, Chief Executive Officer
Age: 43
Bio & Compensation  - Reuters
Zhuo Zhang Vice Chairman of the Board, Chief Financial Officer
Age: 39
Bio & Compensation  - Reuters
Zhicun Chen Independent Director
Age: 43
Bio & Compensation  - Reuters
Hengtong Li Independent Director
Age: 52
Bio & Compensation  - Reuters
Yan Shen Independent Director
Age: 46
Bio & Compensation  - Reuters